ITRK:LSEIntertek Group plc Analysis
Data as of 2026-06-17 - not real-time
£5,680.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Intertek Group plc is trading near its 52‑week high of 5,755 GBp with a current price of 5,680 GBp, well above the DCF‑derived fair value of roughly 2,540 GBp, suggesting the stock is significantly overvalued. Technical metrics show the price sitting above the 20‑day SMA (5,483 GBp) and the 50‑day SMA (5,031 GBp) but the MACD histogram is negative and the MACD line sits below its signal, indicating short‑term bearish momentum despite a bullish overall trend. The RSI of 67 points to an overbought condition, and the next resistance at 5,755 GBp looms close, limiting upside potential.
Fundamentally, the company delivers solid earnings with a 10% profit margin, a strong ROE of 28%, and a healthy dividend yield of 2.9% supported by a 74% payout ratio. Low beta (~0.5) and a 30‑day volatility of 34% reflect modest market sensitivity, while growing trading volume underpins liquidity. No material news items were identified that would materially shift the outlook, leaving the current valuation and operational performance as the primary drivers of the analysis.
Fundamentally, the company delivers solid earnings with a 10% profit margin, a strong ROE of 28%, and a healthy dividend yield of 2.9% supported by a 74% payout ratio. Low beta (~0.5) and a 30‑day volatility of 34% reflect modest market sensitivity, while growing trading volume underpins liquidity. No material news items were identified that would materially shift the outlook, leaving the current valuation and operational performance as the primary drivers of the analysis.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish MACD histogram and overbought RSI
- Price near resistance at 5,755 GBp
- Significant overvaluation relative to DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Stable earnings and cash flow generation
- Attractive dividend yield with sustainable payout
- Moderate valuation gap that may narrow over time
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong ROE and consistent profitability
- Diversified global client base reducing geographic concentration
- Long‑term dividend growth potential despite current overvaluation
Key Metrics & Analysis
Financial Health
Revenue Growth2.00%
Profit Margin10.01%
P/E Ratio26.3
ROE28.24%
ROA9.94%
Debt/Equity146.18
P/B Ratio8.1
Op. Cash Flow£536.5M
Free Cash Flow£362.3M
Industry P/E31.2
Technical Analysis
TrendBullish
RSI67.3
Support£5,310.00
Resistance£5,755.00
MA 20£5,482.75
MA 50£5,030.70
MA 200£4,672.73
MACDBearish
VolumeIncreasing
Fear & Greed Index92.13
Valuation
Fair Value£2,538.00
Target Price£5,849.29
Upside/Downside2.98%
GradeOvervalued
TypeBlend
Dividend Yield2.91%
Risk Assessment
Beta0.49
Volatility34.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.